From the editorial desk

Intervention Profiles

Astaxanthin for longevity: what the human evidence actually shows

A marine carotenoid with antioxidant potency orders of magnitude higher than vitamin E. The human longevity evidence is preliminary — here is an honest assessment.

July 19, 2026  ·  10 min read

Intervention Profiles

DHEA and aging: what the human trial evidence shows

DHEA declines dramatically with age and is one of the most prescribed hormones in longevity medicine. The evidence for hard longevity outcomes is weaker than the prescribing pattern suggests.

July 19, 2026  ·  11 min read

Intervention Profiles

Metformin for longevity: the full evidence profile in 2026

The most-prescribed diabetes drug in history has a compelling longevity hypothesis and some of the strongest observational evidence in the field. Here is the complete evidence picture ahead of TAME results.

July 19, 2026  ·  14 min read

Intervention Profiles

NMN for longevity: the complete evidence profile in 2026

NMN raises NAD+ levels in humans — that much is established. Whether raising NAD+ translates to longevity benefit in healthy adults is the question the current evidence cannot yet answer.

July 19, 2026  ·  13 min read

Intervention Profiles

NR (nicotinamide riboside) for longevity: the complete evidence profile in 2026

NR was the first oral NAD+ precursor to be tested in human RCTs. Here is what those trials showed, how the evidence compares to NMN, and what remains unknown.

July 19, 2026  ·  12 min read

Intervention Profiles

GLP-1 agonists and cardiovascular mortality: a deep dive into the outcome trial data

The SELECT, LEADER, and SUSTAIN-6 trials established GLP-1 agonists as cardiovascular medicines. Here is what that evidence means for longevity medicine specifically.

July 19, 2026  ·  13 min read

Intervention Profiles

Low-dose lithium and longevity: epidemiology, mechanism, and the evidence gap

Epidemiological studies link lithium in drinking water to lower dementia rates and longer lifespan. The human supplementation evidence is sparse — here is what the data shows.

July 19, 2026  ·  10 min read

Clinical Trials

The PEARL trial explained: rapamycin, immune function, and what the 2024 results mean

The PEARL trial is the most important published human trial of rapamycin for aging to date. Here is a detailed breakdown of the design, results, and what they do and do not establish.

July 19, 2026  ·  12 min read

Clinical Trials

TAME trial 2026 update: where the metformin longevity trial stands

The Targeting Aging with Metformin trial is the most significant longevity trial running. Here is the current enrollment status, timeline, and what interim signals look like.

July 19, 2026  ·  11 min read

Clinical Trials

The LIFE study: what the largest exercise trial in older adults found

The Lifestyle Interventions and Independence for Elders study is the most rigorous RCT of physical activity in older adults at risk of mobility disability. What it found — and what it means for longevity medicine.

July 19, 2026  ·  10 min read

Clinical Trials

EMPA-REG OUTCOME explained: what the empagliflozin trial showed for cardiovascular and longevity medicine

The EMPA-REG OUTCOME trial produced one of the most surprising cardiovascular results in recent clinical trial history. Here is a full breakdown of what it found and why it matters for longevity medicine.

July 19, 2026  ·  11 min read

Clinical Trials

DECLARE-TIMI 58: dapagliflozin, cardiovascular outcomes, and the longevity implications

DECLARE-TIMI 58 tested dapagliflozin in a broader, lower-risk population than EMPA-REG. Here is what it found, how it compares, and what the implications are for longevity use.

July 19, 2026  ·  11 min read

Clinical Trials

SELECT trial full breakdown: semaglutide, cardiovascular death, and the longevity question

The SELECT trial showed semaglutide reduced major adverse cardiovascular events in non-diabetic obese adults. Here is the full breakdown of what the trial showed and what it means for longevity medicine.

July 19, 2026  ·  12 min read

Evidence Analysis

How to evaluate a longevity claim: a physician's guide to reading the evidence

Most longevity claims cite evidence. Most of that evidence is misrepresented, misunderstood, or misapplied. Here is a structured framework for evaluating any longevity intervention claim.

July 19, 2026  ·  12 min read

Evidence Analysis

Surrogate endpoints in longevity medicine: what they mean and what they do not prove

Most longevity interventions are studied using surrogate endpoints — epigenetic clocks, inflammatory markers, mitochondrial gene expression. Here is what those endpoints do and do not establish.

July 19, 2026  ·  11 min read